Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.
The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.
The company plans to offer 3.5 million units, comprising one share of common stock and one warrant to buy an additional share, at $2 per unit.
The partners will collaborate on educational and collaborative oncology clinical research activities in India to drive use of genomic technologies.
The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.
By analyzing EMRs and genomic data, Mendel Health believes its AI platform can identify patients for ongoing trials and help clinicians select treatments.
The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.
The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.
Nobel laureate Günter Blobel has died at 81, the New York Times reports.
In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.